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Context: Silent pituitary adenomas are anterior pituitary tumors with hormone synthesis but
without signs or symptoms of hormone hypersecretion. They have been increasingly recognized
and represent challenging diagnostic issues.
Evidence Acquisition: A comprehensive literature search was performed using MEDLINE and
EMBASE databases from January 2000 to March 2018 with the following key words: (i) pituitary
adenoma/tumor and nonfunctioning; or (ii) pituitary adenoma/tumor and silent. All titles and
abstracts of the retrieved articles were reviewed, and recent advances in the field of silent pituitary
adenomas were summarized.
Evidence Synthesis: The clinical and biochemical picture of pituitary adenomas reflects a continuum
between functional and silent adenomas. Although some adenomas are truly silent, others will show
some evidence of biochemical hypersecretion or could have subtle clinical signs and, therefore, can be
referred to as clinically silent or “whispering” adenomas. Silent tumors seem to be more aggressive
than their secreting counterparts, with a greater recurrence rate. Transcription factors for pituitary
cell lineages have been introduced into the 2017WorldHealthOrganization guidelines: steroidogenic
factor 1 staining for gonadotroph lineage; PIT1 (pituitary-specific positive transcription factor 1) for
growth hormone, prolactin, and TSH lineage, and TPIT for the corticotroph lineage. Prospective
studies applying these criteria will establish the value of the new classification.
Conclusions:A concise reviewof the clinical andpathological aspects of silent pituitary adenomaswas
conducted in view of the new World Health Organization classification of pituitary adenomas. New
classifications, novel prognosticsmarkers, and emerging imaging and therapeutic approaches need to
be evaluated to better serve this unique group of patients. (J Clin Endocrinol Metab 104: 2473–2489,
2019)
Pituitary adenomas, more recently referred to as pi-tuitary neuroendocrine tumors in line with neuro-
endocrine tumors (PitNets) from other organs (1), are
common neoplasms comprising ~10% to 20% of in-
tracranial tumors (2). The 2017 World Health Organi-
zation classification for endocrine tumors (3) now defines
pituitary adenomas according to their pituitary hormone
and transcription factor profile (Fig. 1; Table 1) (4). A
sizeable proportion of pituitary adenomas (22% to 54%
in different series) will present with signs and symptoms
of mass effect rather than excessive hormone secretion
and are defined as clinically nonfunctioning pituitary
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Abbreviations: D2R, dopamine receptor D2; DGSA, densely granulated somatotroph ade-
noma; ERa, estrogen receptor a; EZR, ezrin; IHC, immunohistochemistry; MGMT, O-6-
methylguanine-DNA methyltransferase; NFPA, nonfunctioning pituitary adenoma; PC1/3,
prohormone convertase 1/3; POMC, proopiomelanocortin; PRL, prolactin; qRT-PCR, quan-
titative RT-PCR; SCA, silent corticotroph adenoma; SF1, steroidogenic factor 1; SGA,
silent gonadotroph adenoma; SGSA, sparsely granulated somatotroph adenoma; SPA,
silent pituitary adenoma; SSTR, somatostatin receptor; ZAC1, zinc-finger protein
regulator of apoptosis and cell-cycle arrest.
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adenomas (NFPAs) (5–8). The term “silent pituitary
adenoma” (SPA) refers to tumors that express one or
more anterior pituitary hormones or their transcription
factors with immunohistochemistry (IHC) but do not
secrete hormones at a clinically relevant level (9, 10). The
definition of null cell adenoma is restricted to an ex-
ceedingly rare primary adenohypophyseal tumor that is
hormone negative with IHC and does not express any of
the pituitary transcription factors. Therefore, the di-
agnosis of a clinically defined NFPA could be converted
to an SPA if one were to consider the clinical findings of a
nonfunctioning lesion and the pathological features
showing positive hormone or transcription factor staining
(Fig. 2). The present review has focused on SPAs as
defined in this paragraph.
The clinical picture of pituitary adenomas reflects a
continuum between functional adenomas and “totally
silent” adenomas (Fig. 3) (11). The phrase “totally silent”
adenoma has been proposed for when the basal and
stimulated serum concentrations of the corresponding
hormones do not suggest excess hormone secretion and
no clinical signs or symptoms are present that can be
attributed to hormone excess (12). The phrase “clinically
silent” can be usedwhen SPAs secrete hormonal products
that cause a mild elevation of the serum concentration
but do not result in clinical signs or symptoms of hor-
monal hypersecretion (12). Some cases have been re-
ferred to as “whispering” adenomas with borderline,
mild, often overlooked, clinical symptoms and signs but
elevated hormone levels in the blood (11, 13). Further-
more, the functional status of a tumor can change during
the course of the disease, which has most often been seen
with ACTH-expressing tumors (14–16).
A comprehensive literature search was performed
using MEDLINE and EMBASE databases from January
2000 to March 2018 with the following key words:
(1) pituitary adenoma/tumor and nonfunctioning; or
(2) pituitary adenoma/tumor and silent. Two separate
searches were performed in each database without lan-
guage restrictions. A total of 667 studies were retrieved
(PubMed, n = 511; EMBASE, n = 156). Duplicate reports
Figure 1. During pituitary development, specific transcription factors are fundamental to the complex process of adenohypophyseal cell
differentiation. The three main pathways of cell differentiation and the immunoprofile of each cell lineage are illustrated. GATA2, GATA binding
protein-2; PROP1, PROP paired-like homeobox 1 (also called prophet of PIT1); PIT1, POU class 1 homeobox 1 (PUO1F1) or pituitary-specific
positive transcription factor 1; TPIT, T-box transcription factor 19 (TBX19).
Table 1. Classification of Silent Pituitary
Adenomas According to Adenohypophyseal
Hormones and Transcription Factors
Cell Lineage
Pituitary Hormones
by IHC
Transcription
Factors and Other
Cofactors
Somatotroph
adenoma
GH, a-subunit PIT1
Lactotroph
adenomas
PRL PIT1, ERa
Thyrotroph
adenomas
TSHb, a-subunit PIT1, GATA2
Corticotroph
adenomas
ACTH TPIT
Gonadotroph
adenomas
FSHb, LHb, a-subunit SF1, GATA2, ERa
Null cell
adenomas
None None
PIT1-positive
adenomas
GH, PRL, TSHb, a-subunit PIT1
Derived from data from Mete O, Lopes MB. Overview of the 2017 WHO
Classification of Pituitary Tumors. Endocr Pathol 2017; 28:228-243.
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were excluded (n = 55). All titles and abstracts of the
retrieved articles were reviewed, and the data are pre-
sented with an emphasis on the particular aspects of the
different histological subtypes.
General Characteristics
All types and subtypes of hormonally active adeno-
mas can have a silent counterpart. Clinically presenting
NFPAs are typically, although not always, macro-
adenomas, and patients frequently present with symp-
toms related to mass effects, such as headache, visual
disorders, and/or cranial nerve dysfunction (17, 18).
These tumors can also come to medical attention as an
incidental finding when MRI is performed for unrelated
signs and symptoms (19) or, less frequently, as a con-
sequence of anterior pituitary hormonal deficiencies or
hyperprolactinemia due to pituitary stalk compression
(18). Guidelines for the management of incidental NFPAs
have recently been published (20). NFPAs can also
present as sinonasal or nasopharyngeal tumors without
contact with the sella. In such cases, they should be
differentiated from other tumor types occurring in this
region such as primary or metastatic neuroendocrine
tumors or olfactory neuroblastomas (21).
The prevalence of different histological types in a large
surgical series of 1071 pituitary adenomas, including 555
functioning adenomas and 516 SPAs, has been sum-
marized in Table 2 (10). Additionally, Nishioka et al. (10)
showed the value of using a broad panel of cell lineage
transcription factors to further classify hormone-negative
adenomas into the exact type and subtype.
The question to be addressed is whether and how the
management of SPAs would change with an accurate
pathological diagnosis. To date, few studies have re-
ported treatment outcomes with consideration of the full
pituitary hormone and transcription factor profile, be-
cause IHC staining for transcription factors regulating
pituitary development is not yet widely available and
most pathology laboratories still rely solely on pituitary
hormone staining and, often, an incomplete panel.
Nevertheless, the definition of pituitary adenomas accord-
ing to their pituitary hormone and transcription factor
profiles could potentially aid in predicting the disease
course and response to adjunctive therapies.
Null Cell Adenomas and Silent
Gonadotroph Adenomas
Unlike previous classifications (22), the 2017 World
Health Organization “Blue Book” differentiates between
null cell adenomas and silent gonadotroph adenomas
(SGAs). Null cell adenoma is a diagnosis of exclusion that
requires immunonegativity for all adenohypophyseal
hormones and a lack of cell type-specific transcription
factors (23). Null cell adenomas can also show oncocytic
changes, characterized by large cells with cytoplasm
densely filled with coalescent eosinophilic granules on
light microscopy, which correspond, ultrastructurally, to
numerous mitochondria (Fig. 4A and 4B) (24). This
histopathologic finding has been suggested by some to be
Figure 2. Silent pituitary adenoma is a diagnosis that can be
determined by combining the clinical data (clinically nonfunctioning
adenoma) and histopathological data (immunostaining for
hormones and transcription factors).
Figure 3. Continuous spectrum between silent and functioning adenomas.
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an indication of an aging pituitary neuroendocrine tumor
and has not been associated with more aggressive be-
havior in a cohort of pituitary adenomas, including
hormone-negative ones (25).
The introduction of steroidogenic factor 1 (SF1; coded
by the nuclear receptor subfamily 5 group A, member 1
gene) IHC in the diagnosis of pituitary lesions has shown
that many hormone-negative adenomas are, in fact,
SGAs (26). It has been questioned whether null cell
adenomas really exist or if this diagnostic category is
merely a result of methodological diagnostic limitations
(27). The expression of DAX1 (dosage-sensitive sex re-
versal, adrenal hypoplasia critical region, on chromo-
some X, gene 1), a member of the nuclear receptor
superfamily involved with pituitary gonadotroph dif-
ferentiation, was also studied, showing expression in
Table 2. Prevalence of SPAs Among Surgically Resected Pituitary Tumors
Histologic
Type
Percentage of
All Pituitary
Tumors (IHC
for Pituitary
Hormones)
Percentage of
All Pituitary Tumors
(IHC for Pituitary
Hormones and
Transcription
Factors)
Percentage of
Silent Tumors
Within Histologic
Subtype (IHC for
Pituitary Hormones)
Percentage of
Silent Tumors
Within Histologic
Subtype (IHC for
Pituitary Hormones
and Transcription
Factors)
Difference in Invasiveness
and Recurrence Compared
With Silent Gonadotroph
Adenomas
Gonadotroph 28.2 35.6 99.3 99.5 Not applicable
Null cell
adenoma
11.1 0.6 100 100 More invasive; greater
surgical reintervention
rates
GH/PRL/TSH
lineage
46.2 48.4 9.2 9.7 Larger tumor size
Greater recurrence rates
Corticotroph 14.5 17.5 32.9 44.4 Frequently giant adenomas;
marked cavernous sinus
invasion; greater
recurrence rates
Derived from data from Nishioka H, Inoshita N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically
nonfunctioning pituitary adenomas. Endocr Pathol 2015; 26:349-355.
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Figure 4. True null cell adenomas are composed of uniform, mildly atypical cells with chromophobic cytoplasm. (A) An example showing sinusoidal,
papillary, and pseudopapillary architecture similar to the more common gonadotroph adenomas (hematoxylin and eosin stain, 310). (B) A case of
oncocytoma consisting of large cells with acidophilic, granular cytoplasm (hematoxylin and eosin stain, 320). (C and D) Prevalence of the different SPAs
subtypes according to IHC for anterior pituitary hormones: silent gonadotroph adenomas were the most frequent, followed by null cell (according to the
World Health Organization 2004 classification), corticotroph, and GH/prolactin/TSH lineage adenomas. The new classification using IHC for anterior
pituitary hormones and transcription factor profiling substantially reduced the number of null cell adenomas. Derived from data from Nishioka H, Inoshita
N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol
2015; 26:349-355.
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clinically defined NFPAs, even with absent immuno-
staining for pituitary hormones, a-subunit, and SF1 (28).
The preoperative differential diagnosis of NFPAs in-
cludes, in addition to silent pituitary adenomas, primary
non–hormone-secreting lesions such as craniophar-
yngioma, sellar paraganglioma, sellar neuroblastoma,
sellar neurocytoma, metastasis from low-grade neuro-
endocrine tumor, lymphoma, and primary tumors of the
pituitary stalk (29). The diagnostic immunopanel should
therefore be expanded to include cytokeratins, S-100
protein (soluble in saturated 100% ammonium sulfate
solution, a marker of schwannian, melanocytic, or chon-
drocytic tumors), and thyroid transcription factor-1
(a marker of lung and thyroid neoplasms). Correlation
with the clinical history and neuroimaging findings is also
mandatory (30).
The distinction of null cell adenomas and SGAs is of
clinical relevance because null cell adenomas are likely to
be more invasive than are SPAs (31). In a retrospective
series of 516 patients with SPAs, 23.1% of the SPAs were
initially classified as null cell adenomas using pituitary
hormone IHC. However, IHC for PIT1 (pituitary-specific
positive transcription factor 1; coded by the POU class 1
homeobox 1 gene), SF1, TPIT (coded by the T-box
transcription factor 19 gene), and estrogen receptor-a
(ERa) allowed for the identification of mutually exclusive
lineage-specific markers in 95%of the cases, reducing the
prevalence of the null cell adenoma subtype to ~1% (10)
(Fig. 4C and 4D). The remaining genuine null cell ade-
nomas proved to have an unfavorable outcome
compared with hormone-negative but transcription
factor–positive adenomas. In another study, in which the
classification was also based on both adenohypophyseal
hormone and PIT1 and SF1 immunochemistry (TPITwas
not studied), SGAs represented 74.4% of the SPAs (32).
The absence of p27 (cyclin-dependent kinase inhibitor
1B) expression was suggested to be prognostic for null
cell adenomas, with early recurrence, cavernous sinus
invasion, and a Ki-67 labeling index being higher in null
cell adenomas compared to SGAs (31).
Although the vast majority of gonadotroph adenomas
come to medical attention as clinically defined NFPAs,
gonadotrophin secretion, primarily FSH secretion, has
been shown in a high proportion of cases both in vivo and
in vitro. In a cohort of 38 patients with SPAs, consisting
of hormone-negative and gonadotroph adenomas, pre-
operative serum showed a median LH/FSH ratio of 0.33:
1, with 35 of 38 patients presenting with LH/FSH ra-
tios ,1.0. Preferential secretion of FSH was also ob-
served in in vitro culture media, with a median LH/FSH
ratio similar to the preoperative serum ratio (0.32:1). In
contrast, peritumorous “normal” pituitary cells secreted
LH and FSH in an inverted ratio of 3.6:1. These data
suggest, therefore, that a high percentage of these tumors
release FSH into the circulation (33). Even lower serum
LH/FSH ratios have been found in clinically functioning
gonadotroph adenomas compared with SGAs (34).
In a retrospective series of 118 surgically resected
gonadotroph adenomas without symptoms of hyperfunc-
tion, 48% of the men and 25% of the premenopausal
women presentedwith elevated FSHandLH levels; isolated
FSH elevation was more common (13%) than isolated LH
elevation (8%) (35). In a clinicopathological analysis of 100
(79 men and 21 women) gonadotroph adenomas, hypo-
gonadism was diagnosed in 78% of the men, and high
levels of testosterone were not described. Hypersecretion of
FSH and LH (defined as more than a twofold increase
above the upper limit of normal) was observed in 19% and
9% of the men, respectively. In contrast, preoperative FSH
and LH were not elevated in any of the premenopausal or
postmenopausal women. Also, 33% of the patients pre-
sented with hyperprolactinemia, which might have altered
the serum gonadotropin levels (36).
Circulating LH and FSH levels can therefore aid in the
preoperative diagnosis and the postoperative surveillance of
these patients. In men, a large sellar mass associated with
elevated FSH, an inappropriately normal LH, and a low
testosterone level or an elevated LH level, with or without
elevated FSH, and a high testosterone level, is indicative of a
gonadotroph adenoma (12). In premenopausal women, a
gonadotroph adenoma should be suspected when elevated
FSH, low or normal LH, pronounced elevated estradiol are
present with clinical findings resembling polycystic ovar-
ian syndrome, characterized by large polycystic ovaries
and menstrual irregularities (37, 38). In postmenopausal
women, the diagnosis can bemore challenging because they
typically have high circulating gonadotrophins with higher
FSH than LH levels. However, the finding of elevated FSH
with low or low-to-normal LH associated with a very large
sellar mass should suggest the possibility of a gonadotroph
adenoma in this patient group. Measurement of the
a-subunit could also contribute to a preoperative diagnosis
in clinically silent (but biochemically secreting) SPAs, be-
cause it might be the sole biochemical marker of the
gonadotroph subtype in a number of cases (39).
The role of ERa has emerged as a prognostic factor in
male patients with SPAs. Low expression is related to an
earlier and greater repeat intervention rate in male pa-
tients with SGAs. Furthermore, in male patients with
SGA, the combination of the absence of ERa expression
and young age served as good predictive marker for
repeat intervention (32). Androgen receptors are also
often expressed in SGAs (40); however, their significance
is unclear. Because SGAs and hormone-negative pituitary
adenomas represent the most prevalent SPA subtypes,
considerably more data are available on treatment
doi: 10.1210/jc.2018-00688 https://academic.oup.com/jcem 2477
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strategies compared with most other types. Dopamine
receptor type 2 (D2R) and somatostatin receptor (SSTR)
expression have been demonstrated in both gonadotroph
and hormone-negative adenomas, prompting the in-
vestigation of dopamine agonists and somatostatin ana-
logs as potential treatment strategies (41–43).
D2R mRNA expression was demonstrated in two-thirds
(12 of 18) of patients with an adenoma immunonegative for
ACTH, GH, prolactin (PRL), and TSH (44). The nine pa-
tients presenting with residual tumor were treated with
cabergoline,#3mg/wk.After 12months of treatment, tumor
shrinkage was observed in 56% of the patients, and tumor
reduction was significantly greater for those showing D2R
expression (44). In another study of 9 patients with SGAs
(immunonegative for GH, ACTH, PRL, and TSH and pos-
itive for LH, FSH, and/or a-subunit and .50% cells
expressing D2R) with postoperative residual tumor present,
3 mg/week of cabergoline caused a .25% tumor volume
reduction in six of the nine patients after 6 months (45).
Two reference centers in Israel have recently reported
historical cohort analyses on the adjunctive role of a do-
pamine agonist in adult patients with GH- and ACTH-
negative SPAs (46). The treatment group consisted of either
patients who had started dopamine agonist therapy on
detection of postoperative residual tumor (n = 55) or those
whopresentedwith tumor progression during followup (n =
24). The control group (n = 60) received nomedication after
surgery. The dopamine agonist dose was aimed at 10 mg of
bromocriptine daily or 2 mg/week of cabergoline, with a
mean follow-up period of 8.8 6 6.5 years. Tumor control,
defined as tumor shrinkage or stabilization, was achieved in
87.3% of the patients who received treatment on detection
of postoperative residual tumor, in 58.4% of those who
received treatment after presenting with tumor progression,
and in 46.7% of the control group. The requirement for
additional surgery and radiotherapy during the follow-up
period decreased from 46.7% to 16.4% with preventive
treatment. No correlation was found between the clinical
response to the dopamine agonist and D2R expression.
These encouraging results have initiated randomized
controlled trials assessing the effects of cabergoline on
NFPAs currently in progress. A phase III randomized con-
trolled trial (ClinicalTrials.gov identifier, NCT03271918)
assessing the use of cabergoline in patients with ACTH-
negative SPAs who were not cured by surgery has re-
cently been completed, and the results should be available
shortly. In addition, a phase III randomized controlled trial
(ClinicalTrials.gov identifier, NCT02288962) evaluating the
effects of cabergoline on the change in tumor volume, both as
primary treatment and as an adjuvant treatment of post-
operative residual or progressive disease, is ongoing.
Initial studies using the SSTR2 agonist octreotide showed
no or little effect on the tumor growth of clinically defined
NFPAs (47, 48). More recently, a case-control study eval-
uated the results of long-acting octreotide in a cohort of 39
patients with heterogeneous SPAs (76.5% corresponding to
the gonadotroph or hormone-negative types) presenting
with a postoperative residue. The results demonstrated
stabilization of the tumor remnant in 21 of 26 patients
(81%) in the treated group compared with 6 of 13 patients
(47%) in the control group, after amean follow-upperiod of
37 months. However, neither visual field nor pituitary
function was significantly changed in either of the groups,
and no evidence of tumor shrinkage was found in any of the
treated or control patients (49). The limited observed effect
of octreotide on tumor shrinkage in that study could be due
to SSTR5 being the predominant SSTR expressed (84%),
followed by SSTR3 (61%), while SSTR2 was expressed in
only 46% of the cases. SSTR2 expression has been also
shown to be low in SPAs with immunonegative staining
for all pituitary hormones or positive only for glycoprotein
hormones (LH/FSH) compared with active somatotroph
adenomas (42).
The expression of SSTRs and zinc finger protein regu-
lator of apoptosis and cell-cycle arrest (ZAC1), a factor
associated with the response to somatostatin analog ther-
apy in patients with acromegaly (50), was assessed using
quantitative RT-PCR (qRT-PCR) in 20 clinical NFPAs (18
SGAs and 2 hormone-negative adenomas) and compared
with 23 active somatotroph adenomas and 5 normal
pituitaries (51). The expression of SSTR2 and ZAC1 was
decreased and SSTR3 expression was increased in the
hormone-negative tumors and SGAs compared with the
active somatotroph adenomas and normal pituitary (51).
Likewise, other studies have suggested that SSTR3 is the
predominant SSTR expressed in hormone-negative ade-
nomas and SGAs, both by IHC studies and mRNA levels
(32, 43, 52), and SSTR2 expressionwas shown to be absent
in another cohort of true null cell adenomas (32). Some
other studies, however, have reported greater SSTR2 ex-
pression than SSTR3 or SSTR5 in SGAs and hormone-
negative adenomas (53, 54).
An ongoing phase II randomized controlled trial is eval-
uating pasireotide, amultiligand somatostatin analogwith an
action on SSTR1, SSTR2, SSTR3, and STR5 subtypes (55) in
the treatment of clinically defined NFPAs. PASSION-1
(ClinicalTrials.gov identifier, NCT01283542; evaluate the
efficacy and safety of pasireotide LAR on the treatment of
patients with clinically nonfunctioning pituitary adenoma) is
evaluating long-acting pasireotide as primary treatment of
asymptomatic patients with clinically nonfunctioning mac-
roadenomas. Additionally, the results of a phase II ran-
domized controlled trial (ClinicalTrials.gov identifier, NCT
01620138) comparing the effects of cabergoline vs pasireo-
tide in patients with various histological types of SPAs who
were not cured by surgery are expected shortly.
2478 Drummond et al Silent Pituitary Adenomas: A Systematic Review J Clin Endocrinol Metab, July 2019, 104(7):2473–2489
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/104/7/2473/5055109 by Q
ueen M
ary U
niversity of London user on 25 O
ctober 2019
Immune checkpoint inhibitors are widely used in the
treatment of several types of cancers, and damage to the
pituitary gland is one of the well-described side effects.
However, one question is whether they could be used ther-
apeutically for pituitary adenomas. Cytotoxic T-lymphocyte
antigen 4, programmed cell death 1, and its ligand, pro-
grammed cell death ligand 1, are intrinsic downregulators of
immunity and are often overexpressed in the tumor micro-
environment (56). Programmed cell death ligand 1 mRNA
andprotein expression and lymphocytic infiltratewere greater
in functioning pituitary adenomas than in clinically non-
functioning adenomas (hormone-negative adenomas and
SGAs) (57), providing a theoretical rationale for checkpoint
inhibitor treatment of these tumors.
Silent Somatotroph Adenomas
Silent somatotroph adenomas are GH-immunoreactive tu-
mors that lack clinical and biological signs of acromegaly.
They represent ~2% to 4% of all pituitary adenomas in
surgical series (58, 59). Although patients with truly silent
somatotroph adenomas will have normal preoperative GH
and IGF-1 levels (58, 60), other cases will be clinically ap-
parently silent but will show nonsuppressible serumGHand
elevated IGF-1 levels (whispering adenomas) (61–64). In
some cases, in vitroGH secretion with a positive response to
GHRH stimulation has been observed (65). Clinically silent
somatotroph adenomas have also been described in patients
with aryl hydrocarbon receptor-interacting protein muta-
tions, a tumor suppressor gene associated with familial
isolated pituitary adenomas (66). IGF-1 (together with other
biochemical parameters of pituitary function) should be
measured preoperatively in patients with clinically defined
NFPAs (67).
Silent somatotroph adenomas usually express less GH
than their secreting counterparts (58); however, the mech-
anism associated with their reduced GH secretory capacity
has yet to be clarified (67). In cases with very low positivity,
the number of hormone positive cells above which we define
positive immunostaining is not clear and thresholds .1%
or .5% have been used. Moreover, immunostaining for
transcription factors is especially valuable in such cases be-
cause it assists in the challenging differential diagnosis be-
tween scarcely positive immunostaining and normal
entrapped pituitary cells staining for GH/PRL (59).
Secreting somatotroph adenomas are subclassified into
densely granulated (DGSAs) and sparsely granulated
(SGSAs). DGSAs show diffuse and strong positivity for GH
and a-subunit and low-molecular-weight keratin stains in a
perinuclear pattern. In contrast, SGSAs usually show focal or
weak GH expression, no a-subunit expression, and sub-
stantial juxtanuclear globular reactivity for low-molecular-
weight keratin (fibrous bodies). In addition, when a DGSA
presents with scattered fibrous bodies, it can be referred to as
an intermediate type somatotroph adenoma, with its bi-
ological outcomecomparable to that of thedensely granulated
subtype (30). It is important to differentiate between these
two subtypes because secreting SGSAs are usually more ag-
gressive and might not respond well to somatostatin analog
therapy (26).
Similar to functioning somatotroph adenomas, silent
somatotrophadenomas can also be classified intoDGSAs and
SGSAs. Silent somatotroph adenomas are more frequently
sparsely granulated than are active somatotroph adenomas
(58). In a retrospective study that compared 21 silent and
59 secreting somatotroph adenomas, 85.7% of the silent
somatotroph adenomas were SGSAs compared with 45.7%
of their clinically active counterparts, and 95% were mac-
roadenomas with the patients referred for symptoms of mass
effects. The IGF-1 levels were within the normal range. In
addition, compared with clinically functioning somatotroph
adenomas, silent somatotrophadenomasweremore common
in women, presented with a lower percentage of GH im-
munoreactive cells, and were more frequently plurihormonal
(GH/PRL or GH/PRL/TSH). No differences in the marker of
proliferation, Ki-67 labeling index, tumor suppressor p53
expression, or prognostic grades [using the Trouillas classi-
fication (68)] were observed between silent somatotroph
adenomas and secreting somatotroph adenomas.
Similar results were shown in a previous retrospective
study, in which silent somatotroph adenomas accounted
for 7 of 620 (1%) surgically removed pituitary tumors
over 14 years (69). Despite the small sample number, the
investigators concluded that, compared with secreting
somatotroph adenomas, silent somatotroph adenomas
were more frequent in females, presented at a younger
age, and were larger, more invasive, and recurred earlier
and more frequently.
In a recent single-center retrospective surgical series of
pituitary adenomas, silent somatotroph adenomas repre-
sented 2% of the cases (60), and the prevalence of silent
corticotroph adenomas (SCAs; discussed in more detail in
the next section) and SGAs was 4.5% and 18.9%, re-
spectively. In their cohort, silent somatotroph adenomas
were smaller than the SGAs, presented at a younger age,
and showed a substantial female preponderance. On his-
topathological analysis, they expressed GH, with 53% of
cases coexpressing PRL. After a mean follow-up of 3.9
years, nearly one-third of the patients with silent somato-
troph adenomas had experienced tumor progression or
recurrence, and the rates of surgical repeat intervention or
an indication for adjunctive radiation therapy were similar
to those for SCAs but significantly greater than those for
SGAs. Transition to acromegaly was observed in 2 of 17
cases (two female patients developed progression with el-
evated IGF-1 levels during the follow-up period). The
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clinical and pathological characteristics of pure silent GH
adenomaswere comparedwith those of themixedGH/PRL
tumors. Although those findings were limited by the small
sample size, tumors with a pure GH immunoprofile and,
more specifically, the sparsely granulated subtype, were
likely to be larger and more invasive and showed greater
recurrences rates.
The expression of SSTR2 and SSTR5 was recently
demonstrated in all the silent somatotroph adenomas
reviewed (n = 21); however, expression of SSTR2 was
significantly lower compared with the secreting coun-
terpart, and SSTR5 expression was similar in both
groups (58). In another series, the expression of SSTR2
was observed in 6 of 11 cases (.50%); however, SSTR5
expression was not analyzed (60). Clinical data regarding
the therapeutic effect of somatostatin analogs on silent
somatotroph adenomas are not currently available.
Silent Corticotroph Adenomas
Similar to other pituitary tumor types, corticotropinomas
can be either functioning or nonfunctioning (3). SCAwas
the first silent adenoma subtype described as a distinct
clinicopathologic entity (70). SCAs are characterized by
the absence of the clinical features of Cushing syndrome
and normal cortisol dynamics (totally
silent) or elevated ACTH/abnormal
cortisol dynamics (clinically silent) (6,
15, 71, 72). Crooke hyaline changes
(i.e., accumulation of perinuclear
cytokeratin filaments in normal or
neoplastic corticotrophs resulting in a
glassy hyaline appearance on hema-
toxylin and eosin stains) will be absent
in the normal part of the pituitary
owing to the lack of cortisol ex-
cess (4, 73).
SCAs account for 3% to 6% of all
pituitary adenomas, 10% to 20% of
SPAs, and ~40% of all corticotroph cell
tumors (6, 15, 74–76). There is a spec-
trum of functionality of SCAs, and it has
been questioned whether they are truly
silent. Acquired postoperative adrenal
insufficiency has been reported in 20%
to 30% of patients with adenomas that
are apparently SCAs (60), perhaps in-
dicating that these tumors actually se-
crete enough ACTH locally to suppress
ACTH secretion by normal cortico-
trophs (72). A recent, prospective, well-
designed study addressed this question. It
evaluated the hypothalamic–pituitary–
adrenal axis after transsphenoidal surgery in patients with
SCAs compared with patients with ACTH-negative SPAs.
They included patients in whom neither cortisol deficiency
nor cortisol excess was noted in their preoperative as-
sessment (a normal plasma ACTH concentration and a
random serum cortisol level of $12 mg/dL was used to
assess ACTH deficiency; however, dynamic tests such as
dexamethasone suppression or midnight cortisol were not
assessed) (74). During perioperative stress, the pattern and
extent of hypothalamic–pituitary–adrenal axis activa-
tion in patients with SCAs was not different from that in
those with ACTH-negative SPAs, suggesting that these
tumors were truly nonfunctional.
SCAs usually present as macroadenomas associated
with mass-related symptoms (76). Patients with SCAs are
younger than patients with SGAs and true null cell ad-
enomas (32). In contrast to SGAs, SCAs show a female
preponderance, are more frequently giant adenomas, and
are more often associated with marked cavernous sinus
invasion (10). The presence of cystic and hemorrhagic
components in T2-weighted pituitaryMRI sequences in a
NFPA might point toward the corticotroph subtype (77).
In this recent retrospective series, cystic components,
including both macro- and microcysts, were observed on
T2-weighted MRI scans in all patients with SCAs (77). In
Figure 5. Pituitary MRI scans of a silent corticotroph adenoma. (A) T1-weighted MRI sequence
and (B) T2-weighted MRI sequence allowing identification of multiple microcysts. [Figure kindly
provided by Prof. Bonneville, Lyon, France (130)]. Extension to parasellar structures, invasion of
the sellar floor and cystic and hemorrhagic changes can be features of silent corticotroph
adenomas. This example of a cystic silent ACTH adenoma type 2 adenoma had invaded both
clivus and clinoids and extended superiorly to the third ventricle. (C) Axial contrast-enhanced
CT scan). (D) Histologically, the lesion had papillary architecture (hematoxylin and eosin stain,
320). (Inset) A few neoplastic cells expressed ACTH (immunoperoxidase stain, 320). (A and B)
Derived from data from Bonneville F. Silent corticotroph pituitary adenoma. In: Bonneville JF,
Bonneville F, Cattin F, Naggi S, eds. MRI of the Pituitary Gland. Springer; 2016.
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contrast, the specific finding of multiple microcysts was
present in 76% of patients with SCAs vs only 5% of
patients with SGAs (Fig. 5A and 5B). The presence of
multiple microcysts in clinically silent pituitary macro-
adenomas had a sensitivity of 76% and a specificity of
95% for predicting an SCA (77). A correlation between
these MRI findings and pseudopapillary features on
pathological examination was also demonstrated in
patients with SCAs. All the tumors with pseudopapillary
features presented with multiple microcysts on T2-
weighted MRI sequences. The few patients whose T2-
weighted MRI sequences shown no multiple microcysts
had no pseudopapillary features on pathological exam-
ination of the SCA (77).
Corticotroph adenomas can be divided into two subtypes:
type 1 SCA (densely granulated) and type 2 SCA (sparsely
granulated) (6, 10, 30). Type 1 SCAs are indistinguishable
from Cushing-related microadenomas and show strong
ACTH immunoreactivity. Type 2 SCAs resemble the rare
chromophobe corticotroph adenoma and show weak and
focal ACTH immunoreactivity (Fig. 5C and 5D). In such
cases, positive immunostaining for low-molecular-weight
cytokeratin and TPIT will help to confirm the diagnosis
(78). To refine the differential diagnosis between functioning
and silent corticotropinomas, Thodou et al. (79) proposed the
assessment of galectin-3. In their experi-
ence, .80% of SCAs lacked galectin-3
expression, and galectin-3 was uniformly
present in hormonally active adeno-
mas, including a case of Crooke cell
adenoma, a rare and reportedly aggres-
sive variant of corticotroph adenoma
showing Crooke hyaline changes
in .50% of neoplastic cells. Silent
Crooke cell adenomas have been de-
scribed in both adults and children (80,
81). Type 2 SCAs seem to be more
common than type 1 SCAs (9) and have a
tendency to display greater expression of
factors that regulate cell invasion, mi-
gration, and proliferation, such as fibro-
blast growth factor receptor-4, matrix
metalloproteinase-1, and b1-integrin,
compared with type 1 SCAs (82).
Thequestion remaining iswhya tumor
that synthesizes ACTH does not cause the
associated clinical syndrome. One of the
theories that has been proposed is that
the cells originating functioning ACTH-
secreting adenomas or SCAs have dif-
ferent locations within the pituitary
gland. Those associated with Cushing
disease are suggested to arise from the
ACTH-positive cells in the anterior pituitary, and SCAsmight
arise from the proopiomelanocortin (POMC)-producing cells
in the pars intermedia, which, in turn, demonstrates a low
ACTH secretory capacity (72, 83). The hypothesis that
SCAs derive from an intermediate lobe cell that shares
both gonadotroph and corticotroph characteristics is based
on a previous demonstration by electron microscopy and
immunopositivity for transcription factors consistent with
the gonadotroph cell line in a cohort of 18 SCAs (84).
However, this finding was not confirmed in a subsequent
study (60) and requires further investigation. It has also been
proposed that SCAs secrete predominantly high-molecular-
weightACTH,which could competewith the normalACTH
(1 to 39 amino acids) at the receptor level (85). Other
suggested mechanisms include increased intracellular deg-
radation of ACTH and failure of exocytosis of hormone
from the cell membrane (70). An attractive, and currently
most likely, hypothesis is that the clinical manifestations of
Cushing disease are dependent on the processing of the
prohormone POMC in corticotrophs. Prohormone con-
vertase 1/3 (PC1/3) is involved in the post-translational
processing of POMC into mature and biologically active
ACTH (86). Studies have demonstrated a decrease in PC1/3
expression associated with a downregulation of PC1/3 genes
in SCAs compared with corticotroph adenomas associated
Figure 6. Silent corticotroph adenoma: noninvasive macroadenoma. (A) Axial contrast-
enhanced T1-weighted sequence. (B) Histologic slide showing sheets and acini with uniform,
medium-size cells with basophilic cytoplasm (hematoxylin and eosin stain, 320). (C)
Expression of ACTH is diffuse (immunoperoxidase stain, 310). (D) Neoplastic cells show
nuclear expression of the transcription factor TPIT (immunoperoxidase stain, 310). (E) No
expression of PC1/3 was present in the tumor cells (immunoperoxidase stain, 310).
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with Cushing disease (71, 87). The immunohistochemical
features of a PC1/3-negative and ACTH-positive SCA are
illustrated in Fig. 6. In patients with SCAs presenting with
elevatedmean preoperative plasma ACTH levels but normal
serum cortisol levels, POMC expression, measured using
qRT-PCR, was similar to that of corticotroph adenomas
causing Cushing disease and several hundred times greater
than that in hormone-negative adenomas. In contrast, the
expression of PC1/3 was 30-fold higher in those with
Cushing disease compared with that in those with SCAs
(88). The investigators suggested that the elevated ACTH
plasma levels observed in patients with SCAs could reflect
increased circulating POMC detected by the ACTH
plasma immunoassay.
Another intriguing question is how SCAs can evolve
into Cushing disease after years of inactivity. Trans-
formation of an SCA to Cushing disease was first re-
ported in 1985, after an 18-year follow-up period for a
patient who originally had a clinically defined NFPA
(89). Recently, a change in the tumor phenotype, from
SCA to Cushing disease, but also from Cushing disease to
SCA, was reported in 3.9% of SCAs studied, with a
transformation time of 1 to 7 years (15). The expression
of PC1/3 was analyzed by immunochemistry and qRT-
PCR in tissue specimens from both phases in three of the
patients who had presented with transformation from a
SCA to Cushing disease. PC1/3 expression was negative
or weak in the three patients in the initial presenting
phase of SCA, but robust expression was detected in
tissue specimens acquired from the same patients at the
detection of recurrence as Cushing disease (15). These
findings underscore the role of PC1/3 as one of the main
potential mechanisms for “silencing” corticotroph ade-
nomas (Fig. 7) and might provide information on the
mechanisms associated with the other SPA subtypes.
A recent retrospective series of SCAs was reviewed in
the search for predictors of recurrence, comparing the
findings to a cohort of patients with SGAs (60). The SCAs
were of similar size and invasiveness compared with the
SGAs but showed substantially greater recurrence rates
(36% vs 10%), in conjunction with a higher number of
patients with SCAs requiring adjuvant radiotherapy
(18% vs 3%). In this series, none of the patients with
recurrent SCAs had cystic tumors (defined as tumors
with .50% fluid content based on the MRI T2 signal).
The investigators concluded that fewer cystic tumors and
greater preoperative ACTH levels were characteristics
substantially associated with recurrence. Another large
retrospective analysis compared 75 SCAs and 1726
adenomas with negative immunostaining for ACTH,
PRL, and GH (LH/FSH staining was not reported) (88).
The investigators were able to demonstrate that SCAs
were more likely to exhibit cavernous sinus invasion and
greater progression and/or recurrence rates after a mean
follow-up of ~3 years (88).
In contrast to other SPAs, SCAs have demonstrated a
shorter time to recurrence after transsphenoidal surgery
(84) and a higher rate for adenoma progression and
Figure 7. Proposed mechanism for “silencing” of corticotroph adenomas. Reduced PC1/3 activity decreases tumor cell production of ACTH
despite increased levels of POMC. Compared with hormone-negative adenomas, POMC gene expression is increased in pituitary tumor samples
from patients with Cushing disease (CD) and patients with SCAs; however, transcripts for PC1/3 are present at 30-fold greater levels in those
with Cushing disease than in those with SCAs. Derived from data from Jahangiri A, Wagner JR, Pekmezci M, et al. A comprehensive long-term
retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 2013;73:8-18.
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hypopituitarism after stereotactic radiosurgery (90). This
latter retrospective multicenter study evaluated the ef-
fectiveness of stereotactic radiosurgery in 50 patients
with SCAs and 307 patients with other SPA subtypes
who had undergone at least one transsphenoidal surgery
(90). The factors shown to affect tumor progression rates
were the presence of ACTH staining and themargin dose.
Therefore, it has been suggested that in SCAs, an elevated
margin dose might be considered to achieve a better
chance of tumor control.
Two recent retrospective series found no critical risk
factors predicting recurrence after primary or secondary
treatment of SCAs. A single-center retrospective study
evaluated 108 surgically resected SPAs followed for#15
years (91). Of their patients, 22% required further
treatment, either second surgery or radiotherapy (91).
The factors determining recurrence were the presence of
residual tumor, tumor growth rate (.80 mm3/y), and
suprasellar extension. In contrast, the SPA type, cate-
gorized by anterior pituitary hormone immunostaining,
was not a predictive factor for the requirement for sec-
ondary treatment. However, the percentage of SCAs
within the studied SPAs was only 3%, limiting the in-
terpretation of these results (91). In another retrospective
study from two UK reference centers evaluating patients
with SPAs (17% with positive staining for ACTH) who
presented with tumor regrowth after primary treatment,
the anterior pituitary hormone immunostaining profile of
the adenoma was not a substantial factor for further
tumor regrowth (92). The important risk factors were
female sex and treatment modality; the incidence of sec-
ondary regrowth was greater in the conservative monitoring
group (63%) than in the surgery (36%), radiotherapy (13%),
or surgery/adjuvant radiotherapy (13%) groups.
The expression of SSTRs and D2R was evaluated in 8
SCAs using qRT-PCR and compared with 15 ACTH-
negative SPAs and 12 corticotroph tumors associated
with Cushing disease (93). The D2R mRNA levels were
lower in the SCAs and secreting corticotroph adenomas
than in the ACTH-negative SPAs. The SSTR1 mRNA
levels were greater in the SCAs than in the two other
groups, the SSTR2 levels were greater in the SCAs than in
the secreting corticotroph adenomas, and SSTR3 levels
were low and similar in all the groups. The SSTR4 levels
were undetectable, and the SSTR5 levels were detectable,
but lower, in the SCAs compared with the secreting
corticotroph tumors (93). In another study, 15 SCAs
demonstrated greater immunoreactive scores for SSTR2
compared with null cell adenomas (defined in that study
as hormone-, SF1-, and PIT1-negative samples; n = 10)
and greater immunoreactive scores for SSTR5 compared
with SGAs (n = 110) (32). SSTR3 was expressed abun-
dantly by all types of SPAs, including SCAs (32). The
significance of these findings regarding the potential use
of dopamine agonists and, in particular, somatostatin
analogs, in the treatment strategy for SCAs has not yet
been determined. At present, PASSILCORT (pasireo-
tide LAR therapy of silent corticotroph pituitary tumors;
ClinicalTrial.gov identifier, NCT02749227), a phase II
randomized clinical trial, is ongoing, aiming to eval-
uate the results of long-acting pasireotide therapy
for patients with SCAs who present with residual or
recurrent tumors.
Silent Thyrotroph Adenomas
Although increasingly recognized (94), thyrotroph ade-
nomas remain rare (95). These tumors accounted for
3.5% of the operations for pituitary adenomas per-
formed at a single center, and most of these tumors were
clinically silent (96). The most relevant finding of this
series was compared with another large retrospective
series from Japan (97) (Table 3). In both series,.50% of
the silent thyrotroph adenomas presented with extra-
sellar extension, and the most common symptoms were
visual disturbance and headache. When patients with
TSH-expressing adenomas present with hyperthyroid-
ism, the symptoms are often milder than those in patients
with primary hyperthyroidism (98).
Thyrotroph adenomas usually show variable TSHb and
a-subunit expression on IHC (4). Nuclear expression of
PIT1 and its coexpression with GATA-binding protein-2
has been described in several cases (30, 97, 99). The per-
centage of TSHb-expressing cells has been shown to vary
Table 3. Comparison of Clinical Data From Secreting and Silent Thyrotroph Adenomas
Study
TSH-Expressing
Pituitary
Tumors, n
Study
Period
Percentage of
All Pituitary
Tumors
Percentage of
Silent Tumors
Percentage of
Macroadenomas
in Silent Group
Larger Tumor Size
Compared With
Thyrotropinomas
Difference in
Invasiveness/
Recurrence
Compared With
Thyrotropinomas
Kirkman et al.
(96), 2014
32 2002–2012 3.5 75 88 No No
Wang et al.
(97), 2009
29 1975–2001 ,2.4 31 100 Yes No
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widely, ranging from1% to 90%,with significantly greater
expression in patients with hyperthyroidism (96). Fur-
thermore, 84% of cases in that series expressed other
hormones, with no substantial differences between the
secreting and silent subgroups. Also, no difference was
found in the pre- and postoperative imaging findings,
postoperative complications, or recurrence rate (96). One-
third of the patients had developed a recurrence after
a mean follow-up of 80 months; however, consistent
markers of recurrence could not be identified, with no
differences in the percentage of TSH-expressing cells or
Ki-67 index shown (96).
Immunoreactivity for SSTR2 and SSTR5 has been
shown to be positive in 89% and 78% of silent thyro-
troph adenomas, respectively, a difference that was not
significantly different from the hormonally active ade-
nomas (97). TSH-secreting adenomas generally show
excellent hormonal and tumor size response to somato-
statin analog treatment (94, 100–104). Because silent
thyrotropinomas also express SSTRs, somatostatin analog
treatment after surgery when a tumor remnant is present
could be a viable option, as seen in individual cases (105).
Silent Lactotroph Adenomas
Clinically presenting silent lactotroph adenomas are rare.
More frequently, positive PRL expression with IHC is
encountered as a feature of a silent mixed somatotroph-
lactotroph adenoma, a morphological
variant of somatotroph adenomas (60).
According to the German Registry of
Pituitary Tumors, the prevalence of
silent lactotroph adenomas among
SPAs was 1.65%, with most belong-
ing to the sparsely granulated subtype
(9). A recent retrospective surgical
series of SPAs showed an even lower
prevalence of only 0.6% (92). However,
approximately one-half of the micro-
adenomas identified in autopsy studies
have stained positive for PRL (106).
PIT1-Positive
Plurihormonal Adenomas
Formerly known as silent adenoma
type III, PIT1-positive plurihormonal
adenoma is defined as a pluri-
hormonal lesion uniformly express-
ing PIT1 (3, 4). PIT1-positive
plurihormonal adenomas are mono-
morphous; they usually express one
or more hormones of the PIT1 lineage
with only a small portion of them being hormone
negative” (Fig. 8) (107).
PIT1-positive plurihormonal adenomas are a distinct
entity, with reportedly aggressive behavior. A single-center
retrospective series observed a prevalence of 0.9% for
silent subtype 3 adenomas among resected pituitary tu-
mors during a 13-year period. The classificationwas based
on the ultrastructural features, histological aspects, and
immunoreactivity for anterior pituitary hormones. All
tumors were macroadenomas, 60% showed radiographic
features of invasion, and the rate of persistent or recur-
rent disease was .50% during a median follow-up of
51 months (108). These tumors tend to occur in younger
patients, are often not silent, and can present with clinical
symptoms of hormonal excess. Thirty percent of the pa-
tients reviewed in their study presented with hormone
hyperfunction, either GH excess (5 of 27) or substantial
hyperprolactinemia (3 of 27), and 2 patients had a definite
diagnosis of multiple endocrine neoplasia type 1 syn-
drome. In another retrospective series of 25 silent subtype
3 adenomas, substantial hormonal excess was also present
in approximately one-third of the cases, including hy-
perthyroidism in 17%, acromegaly in 8%, and marked
hyperprolactinemia in 4%. Association with the multiple
endocrine neoplasia type 1 syndrome was again reported
in this series in two of the patients who were younger than
30 years and presented with concomitant hyper-
prolactinemia and hyperparathyroidism (107).
Figure 8. A case of a plurihormonal PIT1 adenoma showing the typical diffuse, solid
architecture of this tumor type. (A) It was composed of epithelioid cells with eosinophilic
cytoplasm, an enlarged nucleus, and prominent nucleolus (hematoxylin and eosin stain,
340). (B) Some cells expressed PRL (immunoperoxidase stain, 340). (C) A few tumor cells
were positive for TSH b-subunit (immunoperoxidase stain, 340). (D) Nuclear expression of
the transcription factor PIT1 was ubiquitous (immunoperoxidase stain, 320).
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Aggressive SPAs
The clinical and pathological criteria defining aggressive
adenomas have recently been proposed by a panel of
experts (109). These criteria also apply to SPAs, which,
rarely, can develop into metastatic tumors (110–114).
Temozolomide was the first chemotherapeutic agent to
demonstrate substantial response rates in aggressive pi-
tuitary tumors. Responsiveness to temozolomide is likely
dependent on the immunoexpression of O (6)-methyl-
guanine DNA methyltransferase (MGMT), a DNA repair
protein that acts by removing the alkyl group and inducing
resistance to temozolomide. Low immunoexpression of
MGMT by pituitary tumors has been associated with high
response rates to temozolomide (115).
To date, few case reports have concerned the use of
temozolomide in patients who presented with aggressive
SPAs or who developed pituitary carcinomas several
years after the diagnosis of SPAs (116–119). MGMT
immunoexpression was assessed in a group of 45 SPAs of
various histological subtypes, and the degree of expres-
sion (low expression defined as #50% immunostained
adenoma cells and high as.50%) correlated with tumor
aggressiveness. Low MGMT expression was observed in
50% of the aggressive SPAs compared with 24% in the
nonaggressive SPAs (120). Additionally, MGMT im-
munoreactivity was evaluated in 23 silent subtype 3
adenomas; 78% showed no MGMT immunoreactivity,
17% displayed immunoreactivity in,25% of the tumor
cells, and none of the tumors showed high immunore-
activity (.50%) (121). These findings suggest that ag-
gressive SPAs with low MGMT expression could be
potential candidates for treatment with temozolomide
(115); however, a recent survey performed by the Eu-
ropean Society of Endocrinology showed that, in general,
silent pituitary tumors were less likely to respond
to temozolomide than secreting pituitary tumors, in-
dependent ofMGMT expression status (109). Hormone-
negative pituitary adenomas were more likely to display
highMGMT expression (.50% positive cells) compared
with hormone-positive tumors, irrespective of the func-
tional status. Another interesting finding from that large
cohort of aggressive pituitary tumors (n = 166) was the
high proportion (26%) of initially silent corticotroph or
somatotroph adenomas that evolved into clinically
functioning tumors, again underscoring the continuous
functional spectrum of pituitary adenomas (109).
Future Prospects
The identification of cellular markers predicting tumor
behavior is the “holy grail” of pituitary pathology. The
role of cell proliferation and apoptosis markers in
predicting the recurrence of SPAs has also been in-
vestigated. A high Ki-67 and TUNEL labeling indices and
increased phosphorylated AKT (serine/threonine-specific
protein kinase), phosphorylatedMAPK (p44/42MAPK),
and PTTG1 (pituitary tumor-transforming 1) immuno-
staining were associated with early tumor recurrence
(122). Also, high phosphorylated cyclic AMP response
element-binding protein and ZAC1 expression correlated
inversely with recurrence (122). In another study of 74
SPAs, including SGAs and hormone-negative adenomas,
the Ki-67 index was substantially associated with a tu-
mor size .3 cm and tumor recurrence, suggesting Ki-67
to be a consistent marker of biological behavior in these
subtypes (53). The evaluation of tumor proliferation
using Ki-67 immunochemistry is widely available and
recommended as part of the assessment of SPAs (4).
A recently suggested biomarker for invasiveness of
SPAs is ezrin (EZR) (123).EZR encodes ezrin, also known
as villin-2 or cytovillin, a protein that serves as an in-
termediate between the plasma membrane and the actin
cytoskeleton, in addition to being involved in the regu-
lation of the growth and metastatic capacity of neoplastic
cells (124). Invasive SPAs were shown to have significantly
greater levels of EZR mRNA and of ezrin protein ex-
pression compared with noninvasive SPAs (125).
TGF-b/Smad signaling might be associated with the
development and invasiveness of SPAs (126). TGF-b
signaling is involved in a number of critical processes
such as cell proliferation, differentiation, migration,
apoptosis, and epithelial–mesenchymal transition (127).
Low expression of TGF-b receptor type 2 might be re-
lated to the invasiveness of SPAs, because it has been
shown that TGF-b receptor type 2 protein and mRNA
levels were significantly lower in invasive SPAs compared
with noninvasive SPAs and normal pituitary tissue (128).
Furthermore, TGF-b receptor type 2 mRNA levels
showed a negative correlation with proliferating cell
nuclear antigen, a proliferative marker shown to be
substantially greater in the invasive SPAs in this cohort
(128). With the purpose of investigating further the TGF-
b/Smad signaling role in SPA tumor development, Smad3
and phosphorylated Smad3 protein levels were measured
by immunochemistry in 161 patients with SPAs, including
59 invasive (36.6%) and 102 noninvasive (63.4%) lesions
(129). In agreement with previous findings, the protein
levels of Smad3 and phosphorylated Smad3 were signifi-
cantly lower in patients with invasive SPAs than in non-
invasive SPAs, correlating inversely with the Ki-67 index.
Conclusions
Silent pituitary adenomas represent a challenging diagnostic
group of tumors. Close collaboration of the “pituitary
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team” is essential for a precise diagnosis and will contribute
to the optimal treatment of the patient. New classifications,
novel prognostics markers, and emerging imaging and
therapeutic approaches will need to be evaluated to better
serve this unique group of patients.
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